Afanix 40mg (Afatinib)

Package Insert of  Afanix 40mg (Afatinib)

Description

Afanix 40mg (Afatinib), a 4-anilinoquinazoline tyrosine kinase inhibitor. It  is available as a dimaleate salt under the brand name Gilotrif Label from Boehringer Ingelheim. It is used as the first-line treatment for metastatic non-small cell lung cancer patients with common EGFR. Making it the first FDA-approved oncology product from Boehringer Ingelheim. Afanix 40mg is made by Bangladeshi renowned pharmaceutical Beacon pharmaceutical.

Indications

Afanix 40mg is used as a monotherapy for treating adult patients with metastatic (NSCLC) with non-resistant EGFR mutations. The US FDA approved a supplemental New Drug Application for Afatinib in January 2018, including data on three additional EGFR mutations: L861Q, G719X, and S768I. The drug is indicated for patients with non-resistant EGFR mutations detected by FDA-approved tests.

• First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.
• Treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy.

Mechanism of Actions

Afanix 40mg is a tyrosine kinase inhibitor that blocks the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and HER2 proteins, which are crucial for cell growth, differentiation, and survival.

It works by binding to the kinase domain of EGFR and HER2, preventing them from autophosphorylating and activating downstream signaling pathways. Afanix 40mg is particularly effective against NSCLC tumors with specific mutations in the EGFR gene, making the EGFR protein more active and sensitive to inhibition. It also inhibits the tyrosine kinase activity of HER4, another member of the ErbB family. Afanix 40mg’s anti-cancer effects include inhibiting tumor cell growth and division, promoting tumor cell death, preventing tumor angiogenesis, and inhibiting tumor cell invasion and metastasis. It is a highly effective treatment for NSCLC patients, but potential side effects should be considered.

Dosage and Administration

The recommended dose of Afanix 40mg is 40 mg orally once daily. The recommended dosage of Afanix 40mg in patients with pre-existing severe renal impairment is 30 mg orally once daily.

Afanix 40mg should be taken at least 1 hour before or 2 hours after a meal. This is because food can reduce the absorption of Afanix 40mg.

If you miss a dose of Afanix 40mg, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed dose.

Afanix 40mg should be stored at room temperature away from moisture and heat.

Here are some additional tips for taking afatinib:

• Take afatinib at the same time each day so that you are less likely to forget a dose.
• If you experience any side effects, be sure to talk to your doctor. They may be able to recommend ways to manage your side effects.
• Do not take afatinib if you are pregnant or breastfeeding.
• Be sure to tell your doctor about all of the other medications you are taking, including over-the-counter medications, herbal supplements, and vitamins. Some medications can interact with afatinib and cause serious side effects.

Side Effects

Afatinib can cause mild to severe side effects, including diarrhea, rash, dry skin, nausea, vomiting, fatigue, decreased appetite, stomatitis, weight loss, liver damage, heart problems, lung inflammation, eye problems, kidney problems, nail problems, hair loss, taste changes, infections, bleeding, and bruising. Severe side effects include severe diarrhea, rash, yellowing skin or eyes, dark urine, shortness of breath, chest pain, severe cough, fever, chills, and unusual bleeding or bruising. (5)

Afatinib can also cause rare but serious side effects, such as:

• Stevens-Johnson syndrome (a severe skin reaction)
• Toxic epidermal necrolysis (a life-threatening skin reaction)
• Interstitial lung disease (inflammation of the lungs)
• Heart failure
• Liver failure
• Stroke

Price of Afanix 40mg (Afatinib)

The price of afatinib can vary depending on the country where you live, the pharmacy you use, and your insurance coverage. In the United States, the average price of a 30-day supply of afatinib is around $11,713. However, the price can be much higher for patients who do not have insurance or who have high-deductible insurance plans.

But the price of Afanix 40mg which cost only couple hundreds of dollar and cheap compared to others brand. Which is as effective as other brand’s medicine. To know the exact price inbox us.

Afanix 40mg (Afatinib)FDA Approval

In 2016, the FDA approved afatinib for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy.

In 2018, the FDA expanded the approval of afatinib to include the first-line treatment of patients with metastatic NSCLC whose tumors have non-resistant EGFR mutations as detected by an FDA-approved test.

The FDA approval of afatinib was based on the results of several clinical trials that showed that afatinib was effective in shrinking tumors, prolonging survival, and improving quality of life in patients with NSCLC.

Afanix 40mg (Afatinib) Life Expectency

The life expectancy of patients, who are treated with Afanix 40mg varies depending on a number of factors. That includes the stage of the cancer, the type of EGFR mutation, and the patient’s overall health.

Generally, patients who are treated with Afanix 40mg have a longer life expectancy than patients who are treated with other chemotherapy. In a clinical trial of patients with advanced NSCLC and EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, the median overall survival for patients treated withAfanix 40mg was 13.6 months. In a separate clinical trial of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy, the median overall survival for patients treated with Afanix 40mg was 6.9 months.

See our other product Bevixa, Tagrix-80mg, Alecnib-150mg, Osimert-80mg, Palbonix100/125mg

others medicines like rizonib 250mg, Alectinib are used to treat non-small cell lung cancer